MP0726

MP0726 is a **Radio-DARPin therapeutic candidate** that targets **mesothelin (MSLN)** for the treatment of ovarian cancer. It is designed to deliver targeted alpha-particle therapy via lead-212 (^212Pb), leveraging the high-affinity and selective binding properties of DARPins specifically to the membrane-bound domain of MSLN, minimizing off-target effects and overcoming the historical challenge posed by shed mesothelin acting as a decoy receptor. Preclinical data demonstrate high tumor accumulation (up to 34% at 24 hours post-injection) and a favorable tumor-to-kidney ratio (up to 4.5), which indicates potential for selective tumor targeting with limited kidney uptake. This molecule is co-developed by Molecular Partners and Orano Med, representing the second Radio-DARPin oncology candidate from this collaboration and is still in preclinical development for ovarian cancer[1][2][3][5][7][9].

Other names

212Pb-DARPin MSLNRadio-DARPin MSLN